Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets ...

Increased mixed chimerism, as detected by AlloHeme, could predict post-transplant relapse “with a high degree of accuracy,” said Monzr M. Al Malki, MD.

A team of international scientists has developed a method to predict the risk of developing cancer from a blood disorder common in older adults, according to a study published in the journal Blood.

Swedish company Cantargia has enrolled the first patient in the Phase Ib/IIa trial of nadunolimab for treating individuals ...

FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set ...

Biotech company CERo Therapeutics Holdings, Inc. (CERO) on Wednesday announced an agreement with the University of California ...

Gene mutations in acute myeloid leukemia (AML) cells can guide treatment options, and machine learning can rapidly guess the ...

Hepatic Artery Infusion (HAI) therapy uses a pump that is implanted just below the skin in a patient's abdominal wall to deliver medicine directly to the liver through the hepatic ...

Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...

In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...